Medication reference
Brivaracetam
Monograph awaiting updateThis monograph will be updated in the future.
Historical source. Current clinical review is incomplete. This monograph will be updated in the future.
Brivaracetam (briviact ®) (opens in a new tab)Original source URL: https://globalrph.com/dilution/brivaracetam-briviact/ | Retrieved 2026-11-04
Source dates, location and integrity
This historical article is separate from the reviewed claim cards. Product formulations and source dates may differ.
- Original source URL
- https://globalrph.com/dilution/brivaracetam-briviact/ (opens in a new tab)
- Source date
- Not established in the retrieved source
- Retrieved
- 2026-11-04T19:46:23.588223+00:00
- Source location
- div.post-content
- Packaged content SHA-256
- 1d65173ef0159c56c5b824d751657fa1d4762aab0b7b1c154129f3fc522f8a78
- Original response SHA-256
- 524839b53133ef3def412b9d77a07be39ef40575fa47a672e7a4eea4089132e1
- Source body SHA-256
- d40647a150c0d6a4a51863e638b77649200974d9fc99fec175c81617afa20ac9
BRIVIACT ® (brivaracetam) injection |
|||||||||||||||
|
|||||||||||||||
|
|
|||||||||||||||
Usual Diluents Return to article top |
|||||||||||||||
| NS, D5W, LR | |||||||||||||||
Standard Dilutions [Amount of drug] [Infusion volume] [Infusion rate] Return to article top |
|||||||||||||||
| [Prescribed dose ] [25-100mg] [10-50 ml] [2 to 15 minutes] May also be given undiluted. Dilution above allows for the use of a pvc bag and pump to control the infusion e.g. 50mg/50ml @10 ml/hr. Hepatic Impairment: For all stages of hepatic impairment, the recommended starting dosage is 25 mg twice daily; maximum dosage is 75 mg twice daily. BRIVIACT injection may be used when oral administration is temporarily not feasible. BRIVIACT injection should be administered at the same dosage and same frequency as BRIVIACT tablets and oral solution. The clinical study experience with BRIVIACT injection is limited to 4 consecutive days of treatment. BRIVIACT injection is for single dose only.
|
|||||||||||||||
WARNINGS Return to article top |
|||||||||||||||
| See warnings and precautions below.
|
|||||||||||||||
DESCRIPTION Return to article top |
|||||||||||||||
| Description: The chemical name of BRIVIACT (brivaracetam) is (2S)-2-[(4R)-2-oxo-4-propyltetrahydro-1H-pyrrol-1-yl] butanamide. Initial U.S. Approval: 2016 |
|||||||||||||||
CLINICAL PHARMACOLOGY: Return to article top |
|||||||||||||||
| Mechanism of Action: The precise mechanism by which BRIVIACT exerts its anticonvulsant activity is not known. Brivaracetam displays a high and selective affinity for synaptic vesicle protein 2A (SV2A) in the brain, which may contribute to the anticonvulsant effect. |
|||||||||||||||
INDICATIONS AND USAGE Return to article top |
|||||||||||||||
| BRIVIACT is indicated as adjunctive therapy in the treatment of partial-onset seizures in patients 16 years of age and older with epilepsy.
|
|||||||||||||||
CONTRAINDICATIONS Return to article top |
|||||||||||||||
| Contraindications:: Hypersensitivity to brivaracetam or any of the inactive ingredients in BRIVIACT. |
|||||||||||||||
PRECAUTIONS Return to article top |
|||||||||||||||
| WARNINGS AND PRECAUTIONS:
Suicidal Behavior and Ideation: Monitor patients for suicidal behavior and ideation. (5.1) Neurological Adverse Reactions: Monitor for somnolence and fatigue, and advise patients not to drive or operate machinery until they have gained sufficient experience on BRIVIACT. (5.2) Psychiatric Adverse Reactions: Behavioral reactions including psychotic symptoms, irritability, depression, aggressive behavior, and anxiety; monitor patients for symptoms. (5.3) Hypersensitivity: Bronchospasm and Angioedema: Advise patients to seek immediate medical care. Discontinue and do not restart BRIVIACT if hypersensitivity occurs. (5.4) Withdrawal of Antiepileptic Drugs: BRIVIACT should be gradually withdrawn. (5.5) |
|||||||||||||||
ADVERSE REACTIONS Return to article top |
|||||||||||||||
| ADVERSE REACTIONS:
Most common adverse reactions (at least 5% for BRIVIACT and at least 2% more frequently than placebo) are somnolence/sedation, dizziness, fatigue, and nausea/vomiting. (6.1) To report SUSPECTED ADVERSE REACTIONS, contact UCB, Inc. at 1-844-599-2273 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. See PACKAGE INSERT for PATIENT COUNSELING INFORMATION and Medication Guide. |
|||||||||||||||
DOSAGE AND ADMINISTRATION Return to article top |
|||||||||||||||
| DOSAGE AND ADMINISTRATION: The recommended starting dosage is 50 mg twice daily. Based on individual patient tolerability and therapeutic response, the dosage may be adjusted down to 25 mg twice daily (50 mg per day) or up to 100 mg twice daily (200 mg per day). (2.1) BRIVIACT injection may be used when oral administration is temporarily not feasible. Hepatic Impairment: For all stages of hepatic impairment, the recommended starting dosage is 25 mg twice daily; maximum dosage is 75 mg twice daily. 2.1 Dosage InformationWhen initiating treatment, gradual dose escalation is not required. The recommended starting dosage is 50 mg twice daily (100 mg per day). Based on individual patient tolerability and therapeutic response, the dosage may be adjusted down to 25 mg twice daily (50 mg per day) or up to 100 mg twice daily (200 mg per day) BRIVIACT injection may be used when oral administration is temporarily not feasible. BRIVIACT injection should be administered at the same dosage and same frequency as BRIVIACT tablets and oral solution. The clinical study experience with BRIVIACT injection is limited to 4 consecutive days of treatment. 2.3 Preparation and Administration Instructions for BRIVIACT InjectionBRIVIACT injection is for intravenous use only. Preparation BRIVIACT injection can be administered intravenously without further dilution or may be mixed with diluents listed below.
Administration BRIVIACT injection should be administered intravenously over 2 to 15 minutes. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Product with particulate matter or discoloration should not be used. BRIVIACT injection is for single dose only. 2.4 Discontinuation of BRIVIACTAvoid abrupt withdrawal from BRIVIACT in order to minimize the risk of increased seizure frequency and status epilepticus [see Warnings and Precautions (5.5) and Clinical Studies (14)]. 2.5 Patients with Hepatic ImpairmentFor all stages of hepatic impairment, the recommended starting dosage is 25 mg twice daily (50 mg per day) and the recommended maximum dosage is 75 mg twice daily (150 mg per day) [see Use in Specific Populations (8.7) and Clinical Pharmacology (12.3)]. 2.6 Co-administration with RifampinIncrease the BRIVIACT dosage in patients on concomitant rifampin by up to 100% (i.e., double the dosage)
|
|||||||||||||||
HOW SUPPLIED Return to article top |
|||||||||||||||
| DOSAGE FORMS AND STRENGTHS:
Tablets: 10 mg, 25 mg, 50 mg, 75 mg, and 100 mg (3)
|
|||||||||||||||
Storage and Stability Return to article top |
|||||||||||||||
|
Store at 25°C (77°F); excursions permitted between 15°C to 30°C (59°F to 86°F). See USP Controlled Room Temperature. Do not freeze BRIVIACT injection or oral solution. Discard any unused BRIVIACT oral solution remaining after 5 months of first opening the bottle. BRIVIACT injection vials are single-dose only |
|||||||||||||||
Product identifiers and clinical review status
This monograph will be updated in the future. Historical material is available where present in the original sources; full current exact-product and claim-level review remains pending.
Exact formulation, concentration, container, manufacturer, regulatory identifiers, and a reproducible label snapshot have not all been reconciled.
What remains to be completed
- A retrieved source document is available; clinical reconciliation and a second-source claim map remain incomplete
- Clinically reviewed, individually identified statements with two exact source mappings
- Exact formulation, strength, container, manufacturer/labeler, application and NDC reconciliation
- Renal-function methods and dialysis/CRRT modality review where applicable
- Mechanism provenance, clinical source disagreements and full medication-specific safety reconciliation
Supplemental historical fields
Restored-data provenance and review notes
Source release: 2026-08-31. Current clinical review is incomplete. Original uses of current, verified, or normalized describe the historical source. They do not inherit the status of separately reviewed statements. Product formulations and source dates can differ.
Current review annotations for historical renal, dialysis, mechanism, and product fields
Separate renal reference: Open Renal Dosing Master (opens in a new tab)- Renal
- Status
- not_locally_normalized
- Original classification
- current_label_review_required
- Entries
- General note
- Preserve the source-specific renal-function basis. An indexed CrCl table is not interchangeable with unindexed CrCl or eGFR. Generic advice to check a method does not identify the equation for a dose row.
- Dialysis
- Status
- no_local_structured_regimen
- Entries
- General note
- Named modality alone does not establish applicability. CRRT subtype, effluent rate, residual renal function, timing and interruptions require review. Historical absence is not evidence that no guidance exists.
- Mechanisms
- Source kind
- first_look
- Local pointer
- /mechanism
- Original level
- drug_specific
- Provenance classification
- historical_drug_specific_uncorroborated
- Label derived verified
- false
- Independently corroborated
- false
- Exact label section
- Not recorded
- Original source note
- Not recorded
- Review status
- historical_unverified
- Note
- Drug-specific wording in the old file is not proof of independent corroboration or an exact label locator. Consult separately published current mechanism claims where present.
- Source kind
- label_snapshot
- Local pointer
- /mechanism_summary
- Original level
- drug_specific
- Provenance classification
- historical_drug_specific_uncorroborated
- Label derived verified
- false
- Independently corroborated
- false
- Exact label section
- Not recorded
- Original source note
- Concise GlobalRPh summary reviewed against the selected DailyMed label clinical-pharmacology or microbiology content.
- Review status
- historical_unverified
- Note
- Drug-specific wording in the old file is not proof of independent corroboration or an exact label locator. Consult separately published current mechanism claims where present.
- Future update
- Status
- pending_review
- Message
- This monograph will be updated in the future as current exact-product and claim-level review is completed.
- Source unavailable
- false
- Reason
- The historical content is restored; comprehensive contemporary verification remains incomplete.
Historical first look: uses, mechanism, dosing context, and administration
Recovered v5.1 source content; historical, awaiting current review.
- Id
- brivaracetam
Source ID
H51-FD19508ED88759CE7CE96EFC - Generic name
- Brivaracetam
Source ID
H51-15FD0F7059F06E7EA31DB24B - Class
- Neurology and anticonvulsants
Source ID
H51-C809C7278FA15DC841BE9A40 - Subclass
- SV2A anticonvulsant
Source ID
H51-F60FFDF4B30B3E8ED5902071 - Primary uses
- Partial-onset seizure treatment when oral administration is temporarily not feasible
Source ID
H51-70B9321D65F915C0FF26A1BC
- Partial-onset seizure treatment when oral administration is temporarily not feasible
- Mechanism
- Binds synaptic vesicle protein 2A and modulates neurotransmitter release.
Source ID
H51-8AF39CDB201251305D718454 - Mechanism level
- drug_specific
Source ID
H51-CDA039A9DB917C0CF7DA6937 - Basic dosing orientation
- Adult | Existing preparation record; use current package insert for indication-specific selection | Same total daily dose and frequency as oral regimen | Not normalized in the preparation record | See current package insert and professional guidance | IV infusion; Adult | Prescribed dose | Prescribed dose | Patient- and indication-specific | See current package insert | IV push
Source ID
H51-5DF5B0664AF99E493C020C98 - Administration orientation
- IV injection over 2 to 15 minutes or infusion per label; Over 2 to 15 minutes; 10 mg/mL; Over 2 to 15 minutes
Source ID
H51-D9FB034F69C7D412D880E724 - Renal and population orientation
- Separate renal reference: Open Renal Dosing Master (opens in a new tab)Renal dosing status has not been locally normalized; use the current package insert before ordering or administration.
Source ID
H51-CFD065D98AF4EEBA775C90AC - Key safety orientation
- Somnolence, dizziness, fatigue, and psychiatric adverse reactions.
Source ID
H51-BDD1D2C11BE6AD364AFEFFFE
- Somnolence, dizziness, fatigue, and psychiatric adverse reactions.
- Coverage path
- structured_local_snapshot
Source ID
H51-B9CDFE9C936D6B95ECBF3064 - Coverage path label
- Structured GlobalRPh route snapshot
Source ID
H51-ED7243A7150846F84A749F84 - Official label url
- https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3cf2f439-0e97-443e-8e33-25ecef616f6c (opens in a new tab)
Source ID
H51-0392D64AED2F4B4B13D5F187 - Legacy title
- Brivaracetam (Briviact)
Source ID
H51-3A43E6D2579BE2FB4888E3DD - Review note
- First-look orientation only. Verify indication, patient population, weight basis, organ function, exact IV product, dose, concentration, compatibility, rate, and current labeling before use.
Source ID
H51-A1D2BDA2DFD0F61F2B04165E - Search text
- Brivaracetam Neurology and anticonvulsants SV2A anticonvulsant Partial-onset seizure treatment when oral administration is temporarily not feasible Binds synaptic vesicle protein 2A and modulates neurotransmitter release. Adult | Existing preparation record; use current package insert for indication-specific selection | Same total daily dose and frequency as oral regimen | Not normalized in the preparation record | See current package insert and professional guidance | IV infusion; Adult | Prescribed dose | Prescribed dose | Patient- and indication-specific | See current package insert | IV push IV injection over 2 to 15 minutes or infusion per label; Over 2 to 15 minutes; 10 mg/mL; Over 2 to 15 minutes Renal dosing status has not been locally normalized; use the current package insert before ordering or administration. Somnolence, dizziness, fatigue, and psychiatric adverse reactions. Structured GlobalRPh route snapshot BRIVIACT BRIVIACT (brivaracetam) injection, solution DailyMed label snapshot dosage administration dosage forms strengths mechanism
Source ID
H51-2016070E837A39A50434A79F - Official search url
- https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Brivaracetam (opens in a new tab)
Source ID
H51-C7DF17DAD375168CA7D4F74C - Official access mode
- direct_label
Source ID
H51-1B0962EF6FA9205512C616C4 - Official access url
- https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3cf2f439-0e97-443e-8e33-25ecef616f6c (opens in a new tab)
Source ID
H51-545B8015A6753C914DA251E6 - Official search query
- Brivaracetam
Source ID
H51-FEB8D2555DCDB3A4AC1F8473 - Official access reason
- Very-high-confidence exact IV product label selected during the v5.1 build-time review. Open the current full DailyMed monograph and verify the stocked product before use.
Source ID
H51-DE0E545447D9B5F6C95EABBC - Label snapshot available
- true
Source ID
H51-436079D9E52A2F0784C96E25 - Label snapshot setid
- 3cf2f439-0e97-443e-8e33-25ecef616f6c
Source ID
H51-7D37F72C0D83B87F2F64AB55
No separate structured rows were bundled for continuous infusion, dialysis, CRRT. Historical article content and source links may cover these topics.
Historical dilution and intermittent infusion preparation
Recovered v5.1 source content; historical, awaiting current review.
| Population | Amount | Reconstitution | Diluent | Final volume | Concentration | Rate | Stability | Notes |
|---|---|---|---|---|---|---|---|---|
Source IDH51-8449C72150D4D13B4C4F767DSource IDH51-7ED97EB03D2665FA8014B0B9 | Same total daily dose and frequency as oral regimenSource IDH51-D45DE54C7ADCBE88060B07B9 | No reconstitution required.Source IDH51-19FB8AD00228E64046AF8271 | May be given undiluted or diluted in NS, D5W, or LRSource IDH51-1F59C491812E905E48771DA6 | Syringe or small bagSource IDH51-F9D9FDDE4B841199448E533F | 10 mg/mL undilutedSource IDH51-C03605E858017ACDFDCBBBA6 | IV injection over 2 to 15 minutes or infusion per labelSource IDH51-4B91DC5C8B53BE7A1D66E965 | Use the shorter of current product labeling, validated stability data, and the applicable USP <797> sterility-based BUD ceiling.Source IDH51-6988E04ACFC34DAC30168763 | Use current label for pediatric age eligibility.Source IDH51-09BB193A8BAD7066E26E9E85 |
Historical DailyMed label snapshot
Recovered v5.1 source content; historical, awaiting current review.
- Id
- brivaracetam
Source ID
H51-DBB11503657BD9831C4A0736 - Catalog name
- Brivaracetam
Source ID
H51-0E8D4832772D8255A3F678A3 - Selection status
- accepted_high_confidence
Source ID
H51-34CA0471829F996055A11EB6 - Confidence
- very_high
Source ID
H51-8CDC4C44541311E3231F47DC - Match path
- search_to_exact_label
Source ID
H51-657E71E1428C08A3A9DC3326 - Brand name
- BRIVIACT
Source ID
H51-91055FBEF294EA4BF00A2676 - Label title
- BRIVIACT (brivaracetam) injection, solution
Source ID
H51-9C7BC5299752156989965D2A - Setid
- 3cf2f439-0e97-443e-8e33-25ecef616f6c
Source ID
H51-C662AEF837A85189FBD5E328 - Route
- Intravenous injection or infusion
Source ID
H51-C8C8AF1D70C6A2B849F8BB7B - Dosage form
- Ready-to-use injection solution
Source ID
H51-A7156840E4C0CA56749310CD - Dosage administration summary
- Use the intravenous formulation when oral administration is temporarily not feasible; use the same total daily dose and frequency as the oral regimen.
Source ID
H51-E9C9953E9BB0769ACD5F1042 - Administer intravenously over 2 to 15 minutes. The product may be administered undiluted or after dilution with a label-supported compatible solution.
Source ID
H51-1DFCA956F33BC057430BAA22 - Inspect the solution before use and discard any unused portion of the single-dose vial.
Source ID
H51-178CB9661ECD731847D7E7F3
- Use the intravenous formulation when oral administration is temporarily not feasible; use the same total daily dose and frequency as the oral regimen.
- Dosage forms strengths
- 10 mg/mL injection in a 50 mg/5 mL single-dose vial
Source ID
H51-A7AC145A7BF3409AD80B15B1
- 10 mg/mL injection in a 50 mg/5 mL single-dose vial
- Mechanism summary
- Brivaracetam binds with high affinity to synaptic vesicle protein 2A (SV2A), which is believed to contribute to its antiseizure activity.
Source ID
H51-8EFBB8A8547D9319FEBA319B - Scope note
- The selected BRIVIACT label contains oral and intravenous presentations. This snapshot is limited to the intravenous product.
Source ID
H51-5739834AFF75D6CF856109A3 - Official label url
- https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3cf2f439-0e97-443e-8e33-25ecef616f6c (opens in a new tab)
Source ID
H51-6CAD713E5F32DF646495323B - Reviewed on
- 2026-08-31
Source ID
H51-69F67B3011637650499D33CA - Mechanism source
- Concise GlobalRPh summary reviewed against the selected DailyMed label clinical-pharmacology or microbiology content.
Source ID
H51-5C7DA0FBB35D4ECF1DF15957 - Source sections
- Dosage and Administration
Source ID
H51-751A177FB0A1EE2AEF3F3BE2 - Dosage Forms and Strengths
Source ID
H51-220D14A875C9865EFDEFE564 - Clinical Pharmacology or Microbiology as applicable
Source ID
H51-FD67033D74168D1BDC31821B
- Dosage and Administration
- Retrieval method
- Manual build-time review of the current DailyMed full prescribing information for the selected Set ID; no live server retrieval is required during page use.
Source ID
H51-16A3FDBC9AE564636C6C2808 - Label status
- current
Source ID
H51-FFD5D74D2D509F510E228242 - Disclaimer
- Verify the exact formulation, strength, manufacturer, NDC, route, current label revision, patient-specific order, institutional policy, and monitoring before use.
Source ID
H51-DDA3629128A8E618A090555D
Historical IV-push guidance
Recovered v5.1 source content; historical, awaiting current review.
| Population | Dose scope | Concentration | Rate | Status |
|---|---|---|---|---|
Source IDH51-ABCC83997A29F558CF8A0F99Source IDH51-581FAEF2901265835245046F | Prescribed doseSource IDH51-F30B2F05EADCA9CC17BCCBF0 | 10 mg/mLSource IDH51-FE3DE50682417846789B07F7 | Over 2 to 15 minutesSource IDH51-1161CCC41248BF394DCB950B | Label-standard IV injectionSource IDH51-F856621C4DECFCFFB13F4D0D |
Historical indication and population dosing
Recovered tables and source-separated snapshots; full clinical revalidation remains pending.
Existing dose and route snapshots
| Route | Population | Indication | Dose | Interval | Duration | Administration | Source level | Notes |
|---|---|---|---|---|---|---|---|---|
Source IDH51-A28B077E4E9B5E2A37AA19F8Source IDH51-8D319EC8C0233CE00FAD3784 | AdultSource IDH51-FCC526A990AD29F10FBA308F | Existing preparation record; use current package insert for indication-specific selectionSource IDH51-4DF55135EC2F307A24C0B671 | Same total daily dose and frequency as oral regimenSource IDH51-005C51DE6E454B4089EF7221 | Not normalized in the preparation recordSource IDH51-4C8B6BD7949F7AE88533DA9F | See current package insert and professional guidanceSource IDH51-30D1804F1FC0672054F6DBCC | IV injection over 2 to 15 minutes or infusion per labelSource IDH51-9CA2A9B6D2F087035EF7D90B | Existing GlobalRPh structured preparation snapshotSource IDH51-CAB936D5DB6FFAF5AD47B2A9 | Use current label for pediatric age eligibility.Source IDH51-08BD72550D32EF694674CF37 |
Source IDH51-6A099F3C3D3F2091F4C16ABCSource IDH51-9A98688D28D2B7A28220EA6D | AdultSource IDH51-BFB1793D9E0F6C6530B88DA7 | Prescribed doseSource IDH51-C1A8C8EFC3D446DA84537008 | Prescribed doseSource IDH51-56857255427385FB5759AD9C | Patient- and indication-specificSource IDH51-E1A0992574E77363CF6A1E25 | See current package insertSource IDH51-BBDEB92BB81C4DBDEE7E59EC | Over 2 to 15 minutesSource IDH51-FE530F2DD863C9A2FD3CDF98 | Existing GlobalRPh IV push snapshotSource IDH51-7EFA500B50593DF9E23BC778 | Label-standard IV injectionSource IDH51-C0BFF0FF8C6E915027837B59 |
Historical renal-function guidance
Recovered v5.1 source content; historical, awaiting current review.
Separate renal reference: Open Renal Dosing Master (opens in a new tab)- Classification
- current_label_review_required
Source ID
H51-BA3EB99DFFB51692336742FE - Summary
- Renal dosing status has not been locally normalized; use the current package insert before ordering or administration.
Source ID
H51-41278A5C0E2360094FEFE953 - Method note
- Use the renal function estimate and body-size convention specified by the selected label or institutional protocol. Do not interchange Cockcroft-Gault CrCl, indexed eGFR, and de-indexed eGFR without confirming the dosing source.
Source ID
H51-008CC2F728F1BC23F0C0B7E8
Historical Common IV uses
Recovered v5.1 source content; historical, awaiting current review.
- Partial-onset seizure treatment when oral administration is temporarily not feasible
Source ID
H51-6E85DCEADFC2FFC8AB5E5437
Historical Warnings and safeguards
Recovered v5.1 source content; historical, awaiting current review.
- Somnolence, dizziness, fatigue, and psychiatric adverse reactions.
Source ID
H51-C8DEC066EFD23BAFB03E59AF
Historical Monitoring
Recovered v5.1 source content; historical, awaiting current review.
- Seizure control
Source ID
H51-31068A6A2C4DCC6982B794D0 - Sedation and behavior
Source ID
H51-7CD10BD91F63AEBA4C146C47
Other recovered source fields and original editorial metadata
Original status words such as current, verified, or normalized describe the historical source release. They do not change the clinical review status of this release.
Catalog source fields
Id
brivaracetamSource ID
H51-FB163F3779AC84185704AAF4Generic name
BrivaracetamSource ID
H51-F15CC64A739830BC2E54DD5ABrand names
- Briviact
Source ID
H51-38C5EF22B87158474DCA9741
Class
Neurology and anticonvulsantsSource ID
H51-12068B6EB37B3187FF68EE14Subclass
SV2A anticonvulsantSource ID
H51-03E410A0C115FBEDDABD05B2Summary
Ready-to-use IV anticonvulsant that may be administered undiluted by short IV injection or diluted for infusion.Source ID
H51-2378A44BCAC22290F67FBC7FPopulations
- Adult
Source ID
H51-1E2349ECFC3CA92A38E2469F - Pediatric per current label
Source ID
H51-7246DAB341256D35035F0616
Evidence tier
Core reference - verify current labelSource ID
H51-376FA5921834BCBF7F4EDCA5High alert
falseSource ID
H51-668563667C4AA4ADF795D599Hazardous
falseSource ID
H51-F492B4D80B2A256951D604C8Status
ActiveSource ID
H51-6C85385F8DEA7C2D46CD4A93Reviewed
2026-08-29Source ID
H51-439938CD62BF87984D2A1288Version added
1.2Source ID
H51-8497E54F5E1FDDC6E36932B0Sources
| Label | Url | Kind |
|---|---|---|
Source IDH51-6A9F08ACBEE7A25A8A664733Source IDH51-EC2351F654DD10F410D9148F | https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Brivaracetam (opens in a new tab)Source IDH51-7573FFC60D1C7B2954035AEB | PrimarySource IDH51-E5D2099F5042A03823A4CE44 |
Source IDH51-37F1A52CF72744E860EF4339Source IDH51-8765DC7337672C326E072222 | legacy:autoSource IDH51-629E4DC337F97B7D8E0C7034 | LegacySource IDH51-34FC6C3986310F30CF2D2EFD |
Legacy title
Brivaracetam (Briviact)Source ID
H51-2F67CB20CFBDDB66FEBCE873Clinical release verification
- Audit version
- 3.4
Source ID
H51-240F869E8F7140AC214D4D75 - Audited on
- 2026-08-30
Source ID
H51-AE9D96F548794BFBACB7B0DB - Level
- amber
Source ID
H51-B7DA57471C19C3E0DCA294B4 - Release gate
- trusted_professional_source_present_exact_label_unconfirmed
Source ID
H51-04D3635966FDAF3FA3F6B779 - Exact current label candidate
- false
Source ID
H51-9B115D73FF6FAAEBBEFBF6C1 - Numeric support ratio
- 0
Source ID
H51-8AA4EBDD04B1D1CFD864E268 - Reference url count
- 1
Source ID
H51-082F379B56163E8BF3A861E6 - Broken reference count
- 0
Source ID
H51-78576E04168F4CA9B47882DD - Point of use confirmation required
- true
Source ID
H51-7958D217B26F223D8CEE6FF3 - Note
- Do not treat this record as a fully current product-specific monograph until the exact IV formulation and current sources are confirmed.
Source ID
H51-FDAC0BC79261687D7C930FDD - Dailymed search url
- https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Brivaracetam (opens in a new tab)
Source ID
H51-60C6D32244D2BE5C59D4D540
Version updated
5.1Source ID
H51-AE4B02D4399D9B55461ED604Dosing source fields
Id
brivaracetamSource ID
H51-2C5528878D1D4ADB8A2ED43CGeneric name
BrivaracetamSource ID
H51-5031AE003DAF8ABEC11B2F88Coverage status
direct_official_label_access_plus_local_snapshotSource ID
H51-CF49FD9D35684AD6D63D7DC5Package insert
- Query name
- Brivaracetam
Source ID
H51-A17CD7F72116B356BA782C24 - Product and route must match
- true
Source ID
H51-D82633CD1130357962687014 - Live current label enabled
- false
Source ID
H51-EE436A4E640357E67C3E2F00 - Source priority
- Reviewed local summary when available, then a verified DailyMed label or product search when available, followed by professional references and institutional policy.
Source ID
H51-7A821B7FE19D009551FE627C - Direct official label access enabled
- true
Source ID
H51-BAFD986FD15B28DCF8CCCEAD - Outbound server request required
- false
Source ID
H51-EEEB2EBF79156A096D764475 - Local summary status
- not_bundled
Source ID
H51-A91961FA0986E75A23CD2FD2
Clinical review
- Locally normalized
- false
Source ID
H51-9F83F0793DCA29F3A90C5BCE - Reviewed
- 2026-08-29
Source ID
H51-79AA1D745D3302CA51599268 - Status
- Direct official package-insert access enabled; indication-specific local normalization pending.
Source ID
H51-1A4AE7AC9D8B0B302F203709
Clinical release verification
- Audit version
- 3.4
Source ID
H51-FDA52748F20FAFD4D466B519 - Audited on
- 2026-08-30
Source ID
H51-E4E6BAE13570BCCE76C5A2E2 - Level
- amber
Source ID
H51-690AD8281A1B2DC3730B003E - Release gate
- trusted_professional_source_present_exact_label_unconfirmed
Source ID
H51-393D82F4C5A9D4446FA20782 - Exact current label candidate
- false
Source ID
H51-7BEDF118B43D2A0515232960 - Numeric support ratio
- 0
Source ID
H51-602C1766530443DD4C10FC02 - Reference url count
- 1
Source ID
H51-4A7FF7414891FA0DD6EB8FA5 - Broken reference count
- 0
Source ID
H51-7F13C98A7BCD5F82E7D910C2 - Point of use confirmation required
- true
Source ID
H51-4A100B70D0442908F39C1321 - Note
- Do not treat this record as a fully current product-specific monograph until the exact IV formulation and current sources are confirmed.
Source ID
H51-44A91B230339BCB732E2E74D - Dailymed search url
- https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Brivaracetam (opens in a new tab)
Source ID
H51-91B3485CE35C22C45EFD1B54
Historical preparation assessment
Recovered v5.1 source content; historical, awaiting current review.
- Id
- brivaracetam
Source ID
H51-EB65FFABA10839F3F976CC55 - Name
- Brivaracetam
Source ID
H51-24ADB5C30D0860490B84A618 - Brands
- Briviact
Source ID
H51-39F6830A74676A9B65A99CC9 - Therapeutic class
- Neurology and anticonvulsants
Source ID
H51-5DE715AE81710326C20E6019 - Review version
- 3.1
Source ID
H51-033E65C355DFA36A48429D3B - Review date
- 2026-08-30
Source ID
H51-A9D5F34131BC5391F6F16620 - Release status
- structured_record_current_label_not_confirmed
Source ID
H51-3E5F0994380E5762FFEFF809 - Market status
- Status
- no_current_us_iv_spl_confirmed
Source ID
H51-65B0441674F787963991F602 - Basis
- No high-confidence current IV SPL was automatically selected; legacy information is segregated
Source ID
H51-99DA3C952A5FDE6C42A8A9DD
- Ten point assessment
- Exact formulation
- Not established in the currently normalized record. Use the current-label panel before clinical use.
Source ID
H51-6062F98A78A6D9F6559A300C - Reconstitution concentration
- No reconstitution required.
Source ID
H51-28A774052925702E6A1738C8 - Maximum or recommended final concentration
- Not established in the currently normalized record. Use the current-label panel before clinical use.
Source ID
H51-D1C8AD0767095C3736B65A4B - Appropriate standardized containers
- Syringe or small bag
Source ID
H51-C1B903E22C820EC44AE9A231 - Adult dosing range
- Same total daily dose and frequency as oral regimen Prescribed dose Prescribed dose
Source ID
H51-0EA8BAA93CD7924EC64D5F0B - Pediatric dosing range
- Not established in the currently normalized record. Use the current-label panel before clinical use.
Source ID
H51-80D0EC1E4E0BAC3F889A6EAB - Neonatal dosing range
- Not established in the currently normalized record. Use the current-label panel before clinical use.
Source ID
H51-01F293CE8E5493380A065F2F - Infusion time
- IV injection over 2 to 15 minutes or infusion per label Over 2 to 15 minutes
Source ID
H51-6CF260C8D59A01B539F30634 - Fluid restriction alternatives
- Not established in the currently normalized record. Use the current-label panel before clinical use.
Source ID
H51-EAC236C1F40F60E58932B4FB - Current manufacturer labeling
- Match confidence
- unresolved
Source ID
H51-BBCE0CA071C3080D776BB41B - Url
- https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Brivaracetam (opens in a new tab)
Source ID
H51-99626138024DF0CCE9283326
- Field provenance
- Exact formulation
- Primary
- not_found
Source ID
H51-3F6E63BDA8D8747E287C7113
- Reconstitution concentration
- Primary
- existing_structured_record
Source ID
H51-8015AE6B870D0A11D1692C17
- Maximum or recommended final concentration
- Primary
- not_found
Source ID
H51-509034B7BBA1D6464E6AF688
- Appropriate standardized containers
- Primary
- existing_structured_record
Source ID
H51-A601058D560D3E0AB70B175F
- Adult dosing range
- Primary
- existing_structured_record
Source ID
H51-648066F9A820D56706AEDF6A
- Pediatric dosing range
- Primary
- not_found
Source ID
H51-F43DC52AB1C544E44EB57F67
- Neonatal dosing range
- Primary
- not_found
Source ID
H51-A46356867702AE2EFCC4ED31
- Infusion time
- Primary
- existing_structured_record
Source ID
H51-765B2D18F42C8A34CFEEDDFC
- Fluid restriction alternatives
- Primary
- not_found
Source ID
H51-9DA76151C5B3D6EFD93A9661
- Current manufacturer labeling
- Primary
- DailyMed search gateway
Source ID
H51-85AE4196B3F647410E675783
- Population applicability
- Adult
- Applicability
- supported_or_source_present
Source ID
H51-95A1C25FA2D1B50D854C276C - Guide generation allowed
- true
Source ID
H51-C5E457BBBD950FE24DC6FD11
- Pediatric
- Applicability
- supported_or_source_present
Source ID
H51-56A5671F44EE962EA502B8B3 - Guide generation allowed
- false
Source ID
H51-2EB3453218CC68109A2C8B99
- Neonatal
- Applicability
- not_established
Source ID
H51-77BDE9244A35F690FCC25043 - Guide generation allowed
- false
Source ID
H51-3EC81C71589FE1560C2B4219
- Route presence
- Structured dilution
- true
Source ID
H51-0DAB430BF9E89E175224AD31 - Iv push
- true
Source ID
H51-22651D87A2EA62868E96A349 - Continuous infusion
- false
Source ID
H51-645208885DDBE3DC7C722157 - Pediatric source
- true
Source ID
H51-9A93EB9F581FC2EDD612C0CA - Neonatal source
- false
Source ID
H51-264F6E12EB93AD77E0FDE01D
- Legacy reference
- Status
- not_available
Source ID
H51-BD07D867C8830019F4F4F0AD
- Label resolution
- Status
- build_environment_network_unavailable
Source ID
H51-0301788EAF50AE97B18B699B
- Source files
- catalog.json
Source ID
H51-66214EB0FB9AF85024621E7A - dosing.json
Source ID
H51-DC3FB9F2BF3F94425053E1DF - legacy-map.json
Source ID
H51-2E0CB4C7E49CEA5034A473C0 - new-in-v1.2.json
Source ID
H51-ED9B421CEE8B44FA08FA15E5
- catalog.json
- Clinical release note
- Preparation instructions are released only at the evidence level shown. Legacy content remains visibly separate. Exact product, NDC, route, current labeling, and institutional policy must be confirmed.
Source ID
H51-348EC4DD1C9851405A8A240F
Historical statement IDs and source locations
These IDs identify recovered source units. They are not evidence-qualified clinical claims.
| Historical ID | Original source location | Status |
|---|---|---|
H51-FB163F3779AC84185704AAF4 | catalog.json/records/35/id | Historical; current review incomplete |
H51-F15CC64A739830BC2E54DD5A | catalog.json/records/35/generic_name | Historical; current review incomplete |
H51-38C5EF22B87158474DCA9741 | catalog.json/records/35/brand_names/0 | Historical; current review incomplete |
H51-12068B6EB37B3187FF68EE14 | catalog.json/records/35/class | Historical; current review incomplete |
H51-03E410A0C115FBEDDABD05B2 | catalog.json/records/35/subclass | Historical; current review incomplete |
H51-2378A44BCAC22290F67FBC7F | catalog.json/records/35/summary | Historical; current review incomplete |
H51-6E85DCEADFC2FFC8AB5E5437 | catalog.json/records/35/common_uses/0 | Historical; current review incomplete |
H51-8449C72150D4D13B4C4F767D | catalog.json/records/35/preparations/0 | Historical; current review incomplete |
H51-7ED97EB03D2665FA8014B0B9 | catalog.json/records/35/preparations/0/population | Historical; current review incomplete |
H51-D45DE54C7ADCBE88060B07B9 | catalog.json/records/35/preparations/0/amount | Historical; current review incomplete |
H51-19FB8AD00228E64046AF8271 | catalog.json/records/35/preparations/0/reconstitution | Historical; current review incomplete |
H51-1F59C491812E905E48771DA6 | catalog.json/records/35/preparations/0/diluent | Historical; current review incomplete |
H51-F9D9FDDE4B841199448E533F | catalog.json/records/35/preparations/0/final_volume | Historical; current review incomplete |
H51-C03605E858017ACDFDCBBBA6 | catalog.json/records/35/preparations/0/concentration | Historical; current review incomplete |
H51-4B91DC5C8B53BE7A1D66E965 | catalog.json/records/35/preparations/0/rate | Historical; current review incomplete |
H51-6988E04ACFC34DAC30168763 | catalog.json/records/35/preparations/0/stability | Historical; current review incomplete |
H51-09BB193A8BAD7066E26E9E85 | catalog.json/records/35/preparations/0/notes | Historical; current review incomplete |
H51-ABCC83997A29F558CF8A0F99 | catalog.json/records/35/iv_push/0 | Historical; current review incomplete |
H51-581FAEF2901265835245046F | catalog.json/records/35/iv_push/0/population | Historical; current review incomplete |
H51-F30B2F05EADCA9CC17BCCBF0 | catalog.json/records/35/iv_push/0/dose_scope | Historical; current review incomplete |
H51-FE3DE50682417846789B07F7 | catalog.json/records/35/iv_push/0/concentration | Historical; current review incomplete |
H51-1161CCC41248BF394DCB950B | catalog.json/records/35/iv_push/0/rate | Historical; current review incomplete |
H51-F856621C4DECFCFFB13F4D0D | catalog.json/records/35/iv_push/0/status | Historical; current review incomplete |
H51-7E73A1C6777D7E565106D14C | catalog.json/records/35/iv_push/0/notes | Historical; current review incomplete |
H51-C8DEC066EFD23BAFB03E59AF | catalog.json/records/35/warnings/0 | Historical; current review incomplete |
H51-31068A6A2C4DCC6982B794D0 | catalog.json/records/35/monitoring/0 | Historical; current review incomplete |
H51-7CD10BD91F63AEBA4C146C47 | catalog.json/records/35/monitoring/1 | Historical; current review incomplete |
H51-1E2349ECFC3CA92A38E2469F | catalog.json/records/35/populations/0 | Historical; current review incomplete |
H51-7246DAB341256D35035F0616 | catalog.json/records/35/populations/1 | Historical; current review incomplete |
H51-376FA5921834BCBF7F4EDCA5 | catalog.json/records/35/evidence_tier | Historical; current review incomplete |
H51-668563667C4AA4ADF795D599 | catalog.json/records/35/high_alert | Historical; current review incomplete |
H51-F492B4D80B2A256951D604C8 | catalog.json/records/35/hazardous | Historical; current review incomplete |
H51-6C85385F8DEA7C2D46CD4A93 | catalog.json/records/35/status | Historical; current review incomplete |
H51-439938CD62BF87984D2A1288 | catalog.json/records/35/reviewed | Historical; current review incomplete |
H51-8497E54F5E1FDDC6E36932B0 | catalog.json/records/35/version_added | Historical; current review incomplete |
H51-6A9F08ACBEE7A25A8A664733 | catalog.json/records/35/sources/0 | Historical; current review incomplete |
H51-EC2351F654DD10F410D9148F | catalog.json/records/35/sources/0/label | Historical; current review incomplete |
H51-7573FFC60D1C7B2954035AEB | catalog.json/records/35/sources/0/url | Historical; current review incomplete |
H51-E5D2099F5042A03823A4CE44 | catalog.json/records/35/sources/0/kind | Historical; current review incomplete |
H51-37F1A52CF72744E860EF4339 | catalog.json/records/35/sources/1 | Historical; current review incomplete |
H51-8765DC7337672C326E072222 | catalog.json/records/35/sources/1/label | Historical; current review incomplete |
H51-629E4DC337F97B7D8E0C7034 | catalog.json/records/35/sources/1/url | Historical; current review incomplete |
H51-34FC6C3986310F30CF2D2EFD | catalog.json/records/35/sources/1/kind | Historical; current review incomplete |
H51-2F67CB20CFBDDB66FEBCE873 | catalog.json/records/35/legacy_title | Historical; current review incomplete |
H51-240F869E8F7140AC214D4D75 | catalog.json/records/35/clinical_release_verification/audit_version | Historical; current review incomplete |
H51-AE9D96F548794BFBACB7B0DB | catalog.json/records/35/clinical_release_verification/audited_on | Historical; current review incomplete |
H51-B7DA57471C19C3E0DCA294B4 | catalog.json/records/35/clinical_release_verification/level | Historical; current review incomplete |
H51-04D3635966FDAF3FA3F6B779 | catalog.json/records/35/clinical_release_verification/release_gate | Historical; current review incomplete |
H51-9B115D73FF6FAAEBBEFBF6C1 | catalog.json/records/35/clinical_release_verification/exact_current_label_candidate | Historical; current review incomplete |
H51-2AD9C795F74BA58C3AEAF39A | catalog.json/records/35/clinical_release_verification/selected_setid | Historical; current review incomplete |
H51-97AE8AE8C963C7749C114C7A | catalog.json/records/35/clinical_release_verification/selected_label_title | Historical; current review incomplete |
H51-8AA4EBDD04B1D1CFD864E268 | catalog.json/records/35/clinical_release_verification/numeric_support_ratio | Historical; current review incomplete |
H51-082F379B56163E8BF3A861E6 | catalog.json/records/35/clinical_release_verification/reference_url_count | Historical; current review incomplete |
H51-78576E04168F4CA9B47882DD | catalog.json/records/35/clinical_release_verification/broken_reference_count | Historical; current review incomplete |
H51-7958D217B26F223D8CEE6FF3 | catalog.json/records/35/clinical_release_verification/point_of_use_confirmation_required | Historical; current review incomplete |
H51-FDAC0BC79261687D7C930FDD | catalog.json/records/35/clinical_release_verification/note | Historical; current review incomplete |
H51-60C6D32244D2BE5C59D4D540 | catalog.json/records/35/clinical_release_verification/dailymed_search_url | Historical; current review incomplete |
H51-AE4B02D4399D9B55461ED604 | catalog.json/records/35/version_updated | Historical; current review incomplete |
H51-DBB11503657BD9831C4A0736 | dailymed-label-snapshots-v5.1.json/records/8/id | Historical; current review incomplete |
H51-0E8D4832772D8255A3F678A3 | dailymed-label-snapshots-v5.1.json/records/8/catalog_name | Historical; current review incomplete |
H51-34CA0471829F996055A11EB6 | dailymed-label-snapshots-v5.1.json/records/8/selection_status | Historical; current review incomplete |
H51-8CDC4C44541311E3231F47DC | dailymed-label-snapshots-v5.1.json/records/8/confidence | Historical; current review incomplete |
H51-657E71E1428C08A3A9DC3326 | dailymed-label-snapshots-v5.1.json/records/8/match_path | Historical; current review incomplete |
H51-91055FBEF294EA4BF00A2676 | dailymed-label-snapshots-v5.1.json/records/8/brand_name | Historical; current review incomplete |
H51-9C7BC5299752156989965D2A | dailymed-label-snapshots-v5.1.json/records/8/label_title | Historical; current review incomplete |
H51-C662AEF837A85189FBD5E328 | dailymed-label-snapshots-v5.1.json/records/8/setid | Historical; current review incomplete |
H51-C8C8AF1D70C6A2B849F8BB7B | dailymed-label-snapshots-v5.1.json/records/8/route | Historical; current review incomplete |
H51-A7156840E4C0CA56749310CD | dailymed-label-snapshots-v5.1.json/records/8/dosage_form | Historical; current review incomplete |
H51-E9C9953E9BB0769ACD5F1042 | dailymed-label-snapshots-v5.1.json/records/8/dosage_administration_summary/0 | Historical; current review incomplete |
H51-1DFCA956F33BC057430BAA22 | dailymed-label-snapshots-v5.1.json/records/8/dosage_administration_summary/1 | Historical; current review incomplete |
H51-178CB9661ECD731847D7E7F3 | dailymed-label-snapshots-v5.1.json/records/8/dosage_administration_summary/2 | Historical; current review incomplete |
H51-A7AC145A7BF3409AD80B15B1 | dailymed-label-snapshots-v5.1.json/records/8/dosage_forms_strengths/0 | Historical; current review incomplete |
H51-8EFBB8A8547D9319FEBA319B | dailymed-label-snapshots-v5.1.json/records/8/mechanism_summary | Historical; current review incomplete |
H51-5739834AFF75D6CF856109A3 | dailymed-label-snapshots-v5.1.json/records/8/scope_note | Historical; current review incomplete |
H51-E636FD7602BCA34DB4A5D0AE | dailymed-label-snapshots-v5.1.json/records/8/labeler | Historical; current review incomplete |
H51-6CAD713E5F32DF646495323B | dailymed-label-snapshots-v5.1.json/records/8/official_label_url | Historical; current review incomplete |
H51-69F67B3011637650499D33CA | dailymed-label-snapshots-v5.1.json/records/8/reviewed_on | Historical; current review incomplete |
H51-5C7DA0FBB35D4ECF1DF15957 | dailymed-label-snapshots-v5.1.json/records/8/mechanism_source | Historical; current review incomplete |
H51-751A177FB0A1EE2AEF3F3BE2 | dailymed-label-snapshots-v5.1.json/records/8/source_sections/0 | Historical; current review incomplete |
H51-220D14A875C9865EFDEFE564 | dailymed-label-snapshots-v5.1.json/records/8/source_sections/1 | Historical; current review incomplete |
H51-FD67033D74168D1BDC31821B | dailymed-label-snapshots-v5.1.json/records/8/source_sections/2 | Historical; current review incomplete |
H51-16A3FDBC9AE564636C6C2808 | dailymed-label-snapshots-v5.1.json/records/8/retrieval_method | Historical; current review incomplete |
H51-FFD5D74D2D509F510E228242 | dailymed-label-snapshots-v5.1.json/records/8/label_status | Historical; current review incomplete |
H51-DDA3629128A8E618A090555D | dailymed-label-snapshots-v5.1.json/records/8/disclaimer | Historical; current review incomplete |
H51-2C5528878D1D4ADB8A2ED43C | dosing.json/records/35/id | Historical; current review incomplete |
H51-5031AE003DAF8ABEC11B2F88 | dosing.json/records/35/generic_name | Historical; current review incomplete |
H51-CF49FD9D35684AD6D63D7DC5 | dosing.json/records/35/coverage_status | Historical; current review incomplete |
H51-A17CD7F72116B356BA782C24 | dosing.json/records/35/package_insert/query_name | Historical; current review incomplete |
H51-75A2909A56D8607D783CFC2B | dosing.json/records/35/package_insert/preferred_setid | Historical; current review incomplete |
H51-D82633CD1130357962687014 | dosing.json/records/35/package_insert/product_and_route_must_match | Historical; current review incomplete |
H51-EE436A4E640357E67C3E2F00 | dosing.json/records/35/package_insert/live_current_label_enabled | Historical; current review incomplete |
H51-7A821B7FE19D009551FE627C | dosing.json/records/35/package_insert/source_priority | Historical; current review incomplete |
H51-BAFD986FD15B28DCF8CCCEAD | dosing.json/records/35/package_insert/direct_official_label_access_enabled | Historical; current review incomplete |
H51-EEEB2EBF79156A096D764475 | dosing.json/records/35/package_insert/outbound_server_request_required | Historical; current review incomplete |
H51-A91961FA0986E75A23CD2FD2 | dosing.json/records/35/package_insert/local_summary_status | Historical; current review incomplete |
H51-BA3EB99DFFB51692336742FE | dosing.json/records/35/renal/classification | Historical; current review incomplete |
H51-41278A5C0E2360094FEFE953 | dosing.json/records/35/renal/summary | Historical; current review incomplete |
H51-008CC2F728F1BC23F0C0B7E8 | dosing.json/records/35/renal/method_note | Historical; current review incomplete |
H51-A28B077E4E9B5E2A37AA19F8 | dosing.json/records/35/existing_route_snapshots/0 | Historical; current review incomplete |
H51-8D319EC8C0233CE00FAD3784 | dosing.json/records/35/existing_route_snapshots/0/route | Historical; current review incomplete |
H51-FCC526A990AD29F10FBA308F | dosing.json/records/35/existing_route_snapshots/0/population | Historical; current review incomplete |
H51-4DF55135EC2F307A24C0B671 | dosing.json/records/35/existing_route_snapshots/0/indication | Historical; current review incomplete |
H51-005C51DE6E454B4089EF7221 | dosing.json/records/35/existing_route_snapshots/0/dose | Historical; current review incomplete |
H51-4C8B6BD7949F7AE88533DA9F | dosing.json/records/35/existing_route_snapshots/0/interval | Historical; current review incomplete |
H51-30D1804F1FC0672054F6DBCC | dosing.json/records/35/existing_route_snapshots/0/duration | Historical; current review incomplete |
H51-9CA2A9B6D2F087035EF7D90B | dosing.json/records/35/existing_route_snapshots/0/administration | Historical; current review incomplete |
H51-CAB936D5DB6FFAF5AD47B2A9 | dosing.json/records/35/existing_route_snapshots/0/source_level | Historical; current review incomplete |
H51-08BD72550D32EF694674CF37 | dosing.json/records/35/existing_route_snapshots/0/notes | Historical; current review incomplete |
H51-6A099F3C3D3F2091F4C16ABC | dosing.json/records/35/existing_route_snapshots/1 | Historical; current review incomplete |
H51-9A98688D28D2B7A28220EA6D | dosing.json/records/35/existing_route_snapshots/1/route | Historical; current review incomplete |
H51-BFB1793D9E0F6C6530B88DA7 | dosing.json/records/35/existing_route_snapshots/1/population | Historical; current review incomplete |
H51-C1A8C8EFC3D446DA84537008 | dosing.json/records/35/existing_route_snapshots/1/indication | Historical; current review incomplete |
H51-56857255427385FB5759AD9C | dosing.json/records/35/existing_route_snapshots/1/dose | Historical; current review incomplete |
H51-E1A0992574E77363CF6A1E25 | dosing.json/records/35/existing_route_snapshots/1/interval | Historical; current review incomplete |
H51-BBDEB92BB81C4DBDEE7E59EC | dosing.json/records/35/existing_route_snapshots/1/duration | Historical; current review incomplete |
H51-FE530F2DD863C9A2FD3CDF98 | dosing.json/records/35/existing_route_snapshots/1/administration | Historical; current review incomplete |
H51-7EFA500B50593DF9E23BC778 | dosing.json/records/35/existing_route_snapshots/1/source_level | Historical; current review incomplete |
H51-C0BFF0FF8C6E915027837B59 | dosing.json/records/35/existing_route_snapshots/1/notes | Historical; current review incomplete |
H51-9F83F0793DCA29F3A90C5BCE | dosing.json/records/35/clinical_review/locally_normalized | Historical; current review incomplete |
H51-79AA1D745D3302CA51599268 | dosing.json/records/35/clinical_review/reviewed | Historical; current review incomplete |
H51-1A4AE7AC9D8B0B302F203709 | dosing.json/records/35/clinical_review/status | Historical; current review incomplete |
H51-FDA52748F20FAFD4D466B519 | dosing.json/records/35/clinical_release_verification/audit_version | Historical; current review incomplete |
H51-E4E6BAE13570BCCE76C5A2E2 | dosing.json/records/35/clinical_release_verification/audited_on | Historical; current review incomplete |
H51-690AD8281A1B2DC3730B003E | dosing.json/records/35/clinical_release_verification/level | Historical; current review incomplete |
H51-393D82F4C5A9D4446FA20782 | dosing.json/records/35/clinical_release_verification/release_gate | Historical; current review incomplete |
H51-7BEDF118B43D2A0515232960 | dosing.json/records/35/clinical_release_verification/exact_current_label_candidate | Historical; current review incomplete |
H51-ED02D6D3AE7CE183457ACF36 | dosing.json/records/35/clinical_release_verification/selected_setid | Historical; current review incomplete |
H51-092F48FAC61BA3FB5352170B | dosing.json/records/35/clinical_release_verification/selected_label_title | Historical; current review incomplete |
H51-602C1766530443DD4C10FC02 | dosing.json/records/35/clinical_release_verification/numeric_support_ratio | Historical; current review incomplete |
H51-4A7FF7414891FA0DD6EB8FA5 | dosing.json/records/35/clinical_release_verification/reference_url_count | Historical; current review incomplete |
H51-7F13C98A7BCD5F82E7D910C2 | dosing.json/records/35/clinical_release_verification/broken_reference_count | Historical; current review incomplete |
H51-4A100B70D0442908F39C1321 | dosing.json/records/35/clinical_release_verification/point_of_use_confirmation_required | Historical; current review incomplete |
H51-44A91B230339BCB732E2E74D | dosing.json/records/35/clinical_release_verification/note | Historical; current review incomplete |
H51-91B3485CE35C22C45EFD1B54 | dosing.json/records/35/clinical_release_verification/dailymed_search_url | Historical; current review incomplete |
H51-FD19508ED88759CE7CE96EFC | first-look-v5.1.json/records/35/id | Historical; current review incomplete |
H51-15FD0F7059F06E7EA31DB24B | first-look-v5.1.json/records/35/generic_name | Historical; current review incomplete |
H51-C809C7278FA15DC841BE9A40 | first-look-v5.1.json/records/35/class | Historical; current review incomplete |
H51-F60FFDF4B30B3E8ED5902071 | first-look-v5.1.json/records/35/subclass | Historical; current review incomplete |
H51-70B9321D65F915C0FF26A1BC | first-look-v5.1.json/records/35/primary_uses/0 | Historical; current review incomplete |
H51-8AF39CDB201251305D718454 | first-look-v5.1.json/records/35/mechanism | Historical; current review incomplete |
H51-CDA039A9DB917C0CF7DA6937 | first-look-v5.1.json/records/35/mechanism_level | Historical; current review incomplete |
H51-5DF5B0664AF99E493C020C98 | first-look-v5.1.json/records/35/basic_dosing_orientation | Historical; current review incomplete |
H51-D9FB034F69C7D412D880E724 | first-look-v5.1.json/records/35/administration_orientation | Historical; current review incomplete |
H51-CFD065D98AF4EEBA775C90AC | first-look-v5.1.json/records/35/renal_and_population_orientation | Historical; current review incomplete |
H51-BDD1D2C11BE6AD364AFEFFFE | first-look-v5.1.json/records/35/key_safety_orientation/0 | Historical; current review incomplete |
H51-B9CDFE9C936D6B95ECBF3064 | first-look-v5.1.json/records/35/coverage_path | Historical; current review incomplete |
H51-ED7243A7150846F84A749F84 | first-look-v5.1.json/records/35/coverage_path_label | Historical; current review incomplete |
H51-0392D64AED2F4B4B13D5F187 | first-look-v5.1.json/records/35/official_label_url | Historical; current review incomplete |
H51-3A43E6D2579BE2FB4888E3DD | first-look-v5.1.json/records/35/legacy_title | Historical; current review incomplete |
H51-A1D2BDA2DFD0F61F2B04165E | first-look-v5.1.json/records/35/review_note | Historical; current review incomplete |
H51-2016070E837A39A50434A79F | first-look-v5.1.json/records/35/search_text | Historical; current review incomplete |
H51-C7DF17DAD375168CA7D4F74C | first-look-v5.1.json/records/35/official_search_url | Historical; current review incomplete |
H51-1B0962EF6FA9205512C616C4 | first-look-v5.1.json/records/35/official_access_mode | Historical; current review incomplete |
H51-545B8015A6753C914DA251E6 | first-look-v5.1.json/records/35/official_access_url | Historical; current review incomplete |
H51-FEB8D2555DCDB3A4AC1F8473 | first-look-v5.1.json/records/35/official_search_query | Historical; current review incomplete |
H51-DE0E545447D9B5F6C95EABBC | first-look-v5.1.json/records/35/official_access_reason | Historical; current review incomplete |
H51-436079D9E52A2F0784C96E25 | first-look-v5.1.json/records/35/label_snapshot_available | Historical; current review incomplete |
H51-7D37F72C0D83B87F2F64AB55 | first-look-v5.1.json/records/35/label_snapshot_setid | Historical; current review incomplete |
H51-EB65FFABA10839F3F976CC55 | preparation-assessments-v3.8.json/35/id | Historical; current review incomplete |
H51-24ADB5C30D0860490B84A618 | preparation-assessments-v3.8.json/35/name | Historical; current review incomplete |
H51-39F6830A74676A9B65A99CC9 | preparation-assessments-v3.8.json/35/brands | Historical; current review incomplete |
H51-5DE715AE81710326C20E6019 | preparation-assessments-v3.8.json/35/therapeutic_class | Historical; current review incomplete |
H51-033E65C355DFA36A48429D3B | preparation-assessments-v3.8.json/35/review_version | Historical; current review incomplete |
H51-A9D5F34131BC5391F6F16620 | preparation-assessments-v3.8.json/35/review_date | Historical; current review incomplete |
H51-3E5F0994380E5762FFEFF809 | preparation-assessments-v3.8.json/35/release_status | Historical; current review incomplete |
H51-65B0441674F787963991F602 | preparation-assessments-v3.8.json/35/market_status/status | Historical; current review incomplete |
H51-99DA3C952A5FDE6C42A8A9DD | preparation-assessments-v3.8.json/35/market_status/basis | Historical; current review incomplete |
H51-6062F98A78A6D9F6559A300C | preparation-assessments-v3.8.json/35/ten_point_assessment/exact_formulation | Historical; current review incomplete |
H51-28A774052925702E6A1738C8 | preparation-assessments-v3.8.json/35/ten_point_assessment/reconstitution_concentration | Historical; current review incomplete |
H51-D1C8AD0767095C3736B65A4B | preparation-assessments-v3.8.json/35/ten_point_assessment/maximum_or_recommended_final_concentration | Historical; current review incomplete |
H51-C1B903E22C820EC44AE9A231 | preparation-assessments-v3.8.json/35/ten_point_assessment/appropriate_standardized_containers | Historical; current review incomplete |
H51-0EA8BAA93CD7924EC64D5F0B | preparation-assessments-v3.8.json/35/ten_point_assessment/adult_dosing_range | Historical; current review incomplete |
H51-80D0EC1E4E0BAC3F889A6EAB | preparation-assessments-v3.8.json/35/ten_point_assessment/pediatric_dosing_range | Historical; current review incomplete |
H51-01F293CE8E5493380A065F2F | preparation-assessments-v3.8.json/35/ten_point_assessment/neonatal_dosing_range | Historical; current review incomplete |
H51-6CF260C8D59A01B539F30634 | preparation-assessments-v3.8.json/35/ten_point_assessment/infusion_time | Historical; current review incomplete |
H51-EAC236C1F40F60E58932B4FB | preparation-assessments-v3.8.json/35/ten_point_assessment/fluid_restriction_alternatives | Historical; current review incomplete |
H51-1E6D2C7044EF264C9C65811C | preparation-assessments-v3.8.json/35/ten_point_assessment/current_manufacturer_labeling/setid | Historical; current review incomplete |
H51-C02F180E371239276AD12CEE | preparation-assessments-v3.8.json/35/ten_point_assessment/current_manufacturer_labeling/title | Historical; current review incomplete |
H51-ACABA6630062281D25534C46 | preparation-assessments-v3.8.json/35/ten_point_assessment/current_manufacturer_labeling/published_date | Historical; current review incomplete |
H51-A1196884F50DA704E9C335F0 | preparation-assessments-v3.8.json/35/ten_point_assessment/current_manufacturer_labeling/manufacturer | Historical; current review incomplete |
H51-BBCE0CA071C3080D776BB41B | preparation-assessments-v3.8.json/35/ten_point_assessment/current_manufacturer_labeling/match_confidence | Historical; current review incomplete |
H51-99626138024DF0CCE9283326 | preparation-assessments-v3.8.json/35/ten_point_assessment/current_manufacturer_labeling/url | Historical; current review incomplete |
H51-3F6E63BDA8D8747E287C7113 | preparation-assessments-v3.8.json/35/field_provenance/exact_formulation/primary | Historical; current review incomplete |
H51-8015AE6B870D0A11D1692C17 | preparation-assessments-v3.8.json/35/field_provenance/reconstitution_concentration/primary | Historical; current review incomplete |
H51-509034B7BBA1D6464E6AF688 | preparation-assessments-v3.8.json/35/field_provenance/maximum_or_recommended_final_concentration/primary | Historical; current review incomplete |
H51-A601058D560D3E0AB70B175F | preparation-assessments-v3.8.json/35/field_provenance/appropriate_standardized_containers/primary | Historical; current review incomplete |
H51-648066F9A820D56706AEDF6A | preparation-assessments-v3.8.json/35/field_provenance/adult_dosing_range/primary | Historical; current review incomplete |
H51-F43DC52AB1C544E44EB57F67 | preparation-assessments-v3.8.json/35/field_provenance/pediatric_dosing_range/primary | Historical; current review incomplete |
H51-A46356867702AE2EFCC4ED31 | preparation-assessments-v3.8.json/35/field_provenance/neonatal_dosing_range/primary | Historical; current review incomplete |
H51-765B2D18F42C8A34CFEEDDFC | preparation-assessments-v3.8.json/35/field_provenance/infusion_time/primary | Historical; current review incomplete |
H51-9DA76151C5B3D6EFD93A9661 | preparation-assessments-v3.8.json/35/field_provenance/fluid_restriction_alternatives/primary | Historical; current review incomplete |
H51-85AE4196B3F647410E675783 | preparation-assessments-v3.8.json/35/field_provenance/current_manufacturer_labeling/primary | Historical; current review incomplete |
H51-95A1C25FA2D1B50D854C276C | preparation-assessments-v3.8.json/35/population_applicability/adult/applicability | Historical; current review incomplete |
H51-C5E457BBBD950FE24DC6FD11 | preparation-assessments-v3.8.json/35/population_applicability/adult/guide_generation_allowed | Historical; current review incomplete |
H51-56A5671F44EE962EA502B8B3 | preparation-assessments-v3.8.json/35/population_applicability/pediatric/applicability | Historical; current review incomplete |
H51-2EB3453218CC68109A2C8B99 | preparation-assessments-v3.8.json/35/population_applicability/pediatric/guide_generation_allowed | Historical; current review incomplete |
H51-77BDE9244A35F690FCC25043 | preparation-assessments-v3.8.json/35/population_applicability/neonatal/applicability | Historical; current review incomplete |
H51-3EC81C71589FE1560C2B4219 | preparation-assessments-v3.8.json/35/population_applicability/neonatal/guide_generation_allowed | Historical; current review incomplete |
H51-0DAB430BF9E89E175224AD31 | preparation-assessments-v3.8.json/35/route_presence/structured_dilution | Historical; current review incomplete |
H51-22651D87A2EA62868E96A349 | preparation-assessments-v3.8.json/35/route_presence/iv_push | Historical; current review incomplete |
H51-645208885DDBE3DC7C722157 | preparation-assessments-v3.8.json/35/route_presence/continuous_infusion | Historical; current review incomplete |
H51-9A93EB9F581FC2EDD612C0CA | preparation-assessments-v3.8.json/35/route_presence/pediatric_source | Historical; current review incomplete |
H51-264F6E12EB93AD77E0FDE01D | preparation-assessments-v3.8.json/35/route_presence/neonatal_source | Historical; current review incomplete |
H51-BD07D867C8830019F4F4F0AD | preparation-assessments-v3.8.json/35/legacy_reference/status | Historical; current review incomplete |
H51-0301788EAF50AE97B18B699B | preparation-assessments-v3.8.json/35/label_resolution/status | Historical; current review incomplete |
H51-66214EB0FB9AF85024621E7A | preparation-assessments-v3.8.json/35/source_files/0 | Historical; current review incomplete |
H51-DC3FB9F2BF3F94425053E1DF | preparation-assessments-v3.8.json/35/source_files/1 | Historical; current review incomplete |
H51-2E0CB4C7E49CEA5034A473C0 | preparation-assessments-v3.8.json/35/source_files/2 | Historical; current review incomplete |
H51-ED9B421CEE8B44FA08FA15E5 | preparation-assessments-v3.8.json/35/source_files/3 | Historical; current review incomplete |
H51-348EC4DD1C9851405A8A240F | preparation-assessments-v3.8.json/35/clinical_release_note | Historical; current review incomplete |
Open the original GlobalRPh site monograph (historical; not revalidated) (opens in a new tab)